Biophytis to evaluate BIO101’s potential to limit weight regain in its OBA clinical study in obesity

  • Regulatory protocol amendment filed in Brazil, with submissions planned in the United States and Europe
  • “Rebound effect”: expansion of the scope of BIO101 evaluation following semaglutide discontinuation
  • A new follow-up phase to assess weight regain and the role of BIO101

Biophytis today announces that it has submitted to the Brazilian Health Regulatory Agency (ANVISA) an amendment to the protocol of the phase 2 OBA clinical study in obesity.

Fullscreen Mode

Other Press Releases